News Hub | News Direct

BioNTech's mRNA Vaccine Shows Early Potential Against Pancreatic Cancer

MarketJar

One of the most stubborn, deadly cancers is pancreatic cancer. What if individualized mRNA vaccinations could support the immune system's defense? One of the deadliest forms of cancer around, pancreatic cancer is estimated to kill 88% of patients. It’s also one of the most recurrent cancers, with roughly 90% of patients experiencing a relapse within seven to nine months after surgery. Fortunately, a recent study of an mRNA vaccine for pancreatic cancer patients has provided a glimpse of hope. Scientists at Memorial Sloan Kettering (MSK) Cancer Center in New York just published the results of a small study that the group conducted in partnership with Germany’s BioNTech on pancreatic cancer patients over several years. The study used a pancreatic cancer mRNA vaccine tailored to each patient’s tumor to potentially help provoke an immune response. What’s revolutionary about the vaccines is that the German scientists tailored them to the mutated proteins on the surface of cancer cells instead of a mix of tumor and normal cells, which has been the method tried for decades. The cells were extracted from patients’ tumors by researchers at Memorial Sloan and sent to BioNTech, the company that created the highly-effective COVID-19 vaccine alongside Pfizer. Among the participants in the study, half of the patients’ immune systems learned how to recognize and fight off the cancer cells and showed no signs of relapse during the 18 months they were tracked. While promising, personalized mRNA cancer vaccines are still in their infancy and are too costly to be broadly used. Right now, regular cancer screening remains the best method for detecting cancers, however there are currently no screening tests for pancreatic cancer. Fortunately, that could soon change thanks to Mainz Biomed (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer Developing Early Screening Tests for Colon and Pancreatic Cancers On May 10, Mainz Biomed announced a partnership with Microba Life Sciences for the creation of PancAlert in addition to early colon cancer diagnostics. The technical characteristics of a novel pancreatic cancer screening test with DNA and microbiota indications should be enhanced. As part of the agreement, the two companies will conduct a pilot research project utilizing Microba’s proprietary metagenomic sequencing technology and bioinformatic tools in an effort to discover novel microbiome biomarkers to detect pancreatic cancer. The project, which is expected to run until late 2023, will use Microba's Community Profiler (MCP), a proprietary metagenomic platform technology that has proven to be a best-in-class research tool that can produce comprehensive and accurate species profiles of gastrointestinal samples. Mainz Biomed (NASDAQ:MYNZ) is also focused on commercializing its flagship product ColoAlert, a highly efficacious and simple-to-use detection test for colorectal cancer (CRC) that is already available in select international territories. In Q1 2023, the company also launched a corporate health program in Germany by integrating into BGM, a well-established corporate health program that provides services to employees at 48 of the 50 largest companies in Germany. On May 24, Mainz Biomed announced initial results from its colorectal cancer screening campaign with Zöller-Kipper GmbH through its BGM partnership. In April 2023, Zöller-Kipper selected ColoAlert for its corporate health program, which includes over 2,500 employees. According to the results, employees found the online patient portal easy-to-use and convenient and were able to readily access the portal, request a kit and securely receive results within five days. In order to process the ColoAlert PCR test kit, Mainz Biomed has added Eurofins GeLaMed to its network of lab partners. Eurofins GeLaMed is a division of the global laboratory company Eurofins Scientific, which conducts 450 million tests annually and has over 61,000 employees in 61 nations. Germany is home to four of its locations. Advancing Towards FDA Approval to Bring ColoAlert to the US Market Over the last few months, Mainz Biomed has continued to prepare for patient enrollment in its pivotal clinical trial for ColoAlert after successfully completing its pre-submission process with the FDA. ColoAlert will be examined in the FDA-registered trial "ReconAAsense" in order to obtain commercial approval in the United States. The company's business objective is to create scalable distribution across the nation once it receives approval through a cooperative partner program with regional and national laboratory service providers. Learn more about Mainz Biomed (NASDAQ:MYNZ) and its activities by clicking on this link. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Mainz Biomed NV. Market Jar Media Inc. has or expects to receive from Mainz Biomed NV’s Digital Marketing Agency of Record (Native Ads Inc.) eighty nine thousand seven hundred sixty four USD for 12 days (9 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mainz Biomed NV’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mainz Biomed NV’s industry; (b) market opportunity; (c) Mainz Biomed NV’s business plans and strategies; (d) services that Mainz Biomed NV intends to offer; (e) Mainz Biomed NV’s milestone projections and targets; (f) Mainz Biomed NV’s expectations regarding receipt of approval for regulatory applications; (g) Mainz Biomed NV’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mainz Biomed NV’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mainz Biomed NV’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mainz Biomed NV’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mainz Biomed NV’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Mainz Biomed NV’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mainz Biomed NV to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mainz Biomed NV’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Mainz Biomed NV’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mainz Biomed NV’s business operations (e) Mainz Biomed NV may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Mainz Biomed NV undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mainz Biomed NV nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mainz Biomed NV nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mainz Biomed NV or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mainz Biomed NV or such entities and are not necessarily indicative of future performance of Mainz Biomed NV or such entities. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

May 24, 2023 09:00 AM Eastern Daylight Time

Image

OYO Launches Discounted Stays as Memorial Day Weekend Bookings Soar

OYO

Global travel technology company OYO has announced a special offer for the upcoming Memorial Day holiday. This Memorial Day weekend is expected to be the busiest since 2000. Due to record anticipated travelers for the weekend, OYO is offering discounted stays to help travelers plan their holidays within their budget. Travelers can avail 33% off on all stays from 27 th to 31 st May 2023. With this 33% off discount offer, travelers can book 2 nights and get 1 night stay for free at select OYO hotels across the US. To redeem the offer, customers need to book their stay on the OYO app or website and enter the promo code “MEMORIALDAY.” Customers can also book by calling our representatives on +1 405-342-7056. OYO is also seeing increased demand in cities like Atlanta, Houston, San Antonio & Jackson. Speaking about the upcoming season, Gautam Swaroop, CEO OYO International said, “Memorial Day is an important holiday for the Americans. We are preparing for the busy summer season across the states, which officially kicks off this weekend. We anticipate a surge in bookings, as reports suggest that 42.3 million Americans will be traveling 50 miles or more for the long weekend, an increase of 2.7 million compared to 2022. We expect record-breaking hotel bookings within city limits and along highways, as a vast majority of Americans, approximately 37.1 million travelers, will be hitting the road.” OYO offers hotels access to a large base of regular customers through its app and website, and lists hotels on multiple Online Travel Agents (OTAs) to boost booking demand and revenue. OYO’s best-in-class Artificial Intelligence-enabled pricing software automatically drives the best booking prices across all channels, based on room type, seasonality and other factors, therefore, enabling such an increase in online revenues. OYO has started offering hotels the flexibility of not having to invest heavily in redoing the hotel to join the OYO platform, something that other budget hotel chains insist on. Therefore, the initial investment to join OYO is minimal. It has been focusing instead on standardizing service led components such as customer support and booking experience. The company helps ensure great experience for customers, with ease of search and a quick booking experience, highly competitive room prices as per market demand patterns, automated tools such as Artificial Intelligence powered chatbots to quickly resolve customer queries, loyalty programs and easy refund, if needed. Earlier this year OYO said that it is planning to add over 100 hotels in the US in 2023. This is nearly double the number of hotels the company added to its portfolio in 2022. OYO will focus on adding more hotels in the states of Oregon, Washington, Texas, Oklahoma, Georgia and Florida. Texas continues to be the largest and fastest growing market for OYO in the US, while it also has sizable concentration of hotels in Oregon, South and North Carolina, Florida & Georgia. In 2022, the company saw a ~23% increase in new hotels added to its portfolio in the US vs 2021. Furthermore, OYO’s US operations have outpaced the budget hotel segment in terms of revenue per available room (RevPar) with an 18% rise in RevPar in 2022 vs pre-covid year, 2019. In contrast the budget hotel segment grew by only 6% in the US. The company also achieved a 48% growth in revenue from bookings on its own platform, such as the app, website, mobile web and call centers in Q4 2022 vs same period in 2021. OYO’s app saw highest growth with a 99% surge in revenue from bookings in Q4 2022 vs same period in 2021. The company had earlier disclosed that its app is the second most downloaded travel app with over 100 million downloads globally. About OYO: OYO is a global platform that aims to empower entrepreneurs and small businesses with hotels and homes by providing full-stack technology products and services that aim to increase revenue and ease operations; bringing easy-to-book, affordable, and trusted accommodation to customers around the world. OYO offers 40+ integrated products and solutions to patrons who operate over 168,711 hotel and home storefronts in more than 35 countries including India, Europe and Southeast Asia, as of September 30, 2022. For more information, visit www.oyorooms.com. Disclaimer: Oravel Stays Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its equity shares (the “Equity Shares”) and has filed the Draft Red Herring Prospectus (“DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges, i.e., BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the Global Coordinators and Book Running Lead Managers, i.e., Kotak Mahindra Capital Company Limited, J.P. Morgan India Private Limited and Citigroup Global Markets India Private Limited at www.investmentbank.kotak.com, www.jpmipl.com and www.online.citibank.co.in/rhtm/citigroupglobalscreen1.htm; the websites of the Book Running Lead Managers, i.e., ICICI Securities Limited, Nomura Financial Advisory and Securities (India) Private Limited, JM Financial Limited and Deutsche Equities India Private Limited at www.icicisecurities.com, www.nomuraholdings.com/company/group/asia/india/index.html, www.jmfl.com and www.db.com/India, respectively. Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, refer to the Red Herring Prospectus which may be filed with the Registrar of Companies in the future, including the section titled “Risk Factors”. Potential investors should not rely on the DRHP filed with SEBI for making any investment decision. The Equity Shares offered in the Fresh Issue (as defined in the DRHP) and the Offer for Sale (as defined in the DRHP) have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and, may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States only to “qualified institutional buyers” (as defined in Rule 144A under the Securities Act) in transactions exempt from, or not subject to, the registration requirements under the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and pursuant to the applicable laws of the jurisdictions where those offers and sales are made. There will be no public offering of the Equity Shares in the United States. Contact Details Anupriya +91 97911 63065 anupriya.d@oyorooms.com Company Website https://www.oyorooms.com/

May 23, 2023 11:00 AM Eastern Daylight Time

Emergent Health and Apollo Biowellness Announce Strategic Collaboration

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today that it will be collaborating with Apollo Biowellness, Inc., the entity that Boustead has engaged to conduct an IPO of the roll up of the regenerative medicine space, previously announced by Emergent on May 18, 2023. Apollo is an aggregate of manufacturing, distribution and marketing of regenerative products and brands in the regenerative space. This partnership, along with the previously announced spin-off of PharmaZu will continue to build significant value to Emergent. As part of the roll-up being conducted by Boustead and Apollo Biowellness, effective June 1, 2023, Mr. Morrison will take over as President/CEO of Apollo Biowellness. Mr. Morrison will remain as a member of the Board of Directors of the Emergent and will assume the Title of Chairman of the Board. He will continue to be intimately involved with Emergent and the continued development, marketing and distribution of its products and brands, The two companies will coordinate marketing strategies, manufacturing and work together to expand the products and brands. Jim Morrison stated, “Since taking the helm of Emergent, I have enjoyed the process of creating the Company’s vibrant products and brands in the regenerative biologic space. The opportunity to coordinate between Emergent and Apollo and expand the value of these products and brands as President of Apollo Biowellness is an exciting opportunity and will bring expanded value to Emergent. I look forward to continuing to be involved in the dynamic offerings of Emergent going forward.” Jim Zimbler, a member of the Board of Directors, and previously the President of the Company, has been re-appointed as Interim President of the Company, also effective June 1, 2023. In addition to bringing on new senior management, the Company will be announcing a new CFO and a will conduct a new executive search for a new permanent full time CEO to work with the current management and Board and team and Mr. Morrison and the Apollo Biowellness team. The Company will announce more Management updates shortly. Jim Zimbler stated, “Jim Morrison has done a magnificent job during his tenure as President, and I know he will be a tremendous asset to Apollo Biowellness. I look forward to a close continued relationship with Mr. Morrison and leaning on him for his sizable experience and tutelage related to products and brands. That will greatly enhance the value Emergent will receive from the sale of Evolutionary Biologics and the other entities.” ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, Chairman of the Board James W. Zimbler – Interim President/Interim CEO Emergent Health Corporation Website i nfo@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 23, 2023 09:00 AM Eastern Daylight Time

The Humane Society of the United States Addresses the Pet Poverty Crisis

YourUpdateTV

Most people are aware of how poverty and structural inequality create challenges and barriers to accessing healthy food, education, jobs, health care and housing and how inflation is only making the crisis worse. Pet resources are no different. Many families are struggling to afford and access veterinary care, food and supplies for their beloved pets. More than 20 million pets live in poverty - three times as many pets live in poverty as enter shelters every year. This is a long overlooked national crisis exacerbated by inflation and the economy. Recently, Kitty Block, President and CEO of the Humane Society of the United States, participated in a nationwide satellite media tour to discuss the launch of the More Than a Pet campaign and how the organization is addressing the crisis. A video accompanying this announcement is available at: https://youtu.be/GdaZXktSjNI Over the past 20 years, the Humane Society of the United States has helped half a million pets and their families by providing veterinary care and supplies at no cost, keeping families and pets together in over 50 communities across the U.S. Without these services, families are often forced to make choices about sacrificing their own needs, even food and medications for themselves, to prioritize care for their pet. No family should ever have to make that choice. Since 2002, the Humane Society of United States’ Pets for Life and Rural Area Veterinary Services programs have been helping pet owners across the U.S. by providing food, supplies and services for their cats and dogs at no cost. It is critical to close the gap that exists for people and pets in underserved areas. With the new campaign called “More Than a Pet,” the HSUS is sounding an alarm about this crisis that is only getting worse. The Humane Society of the United States is offering these tips for people to support their communities: Advocate for keeping pets and their people together by signing the HSUS petition to close the pet equity gap. Your voice can make a big impact for all animals. Volunteer with the Humane Society of the United States’ Pets for Life and Rural Area Veterinary Services programs, which increase access to pet care for underserved communities. Donate pet food to your local shelter or pet food pantry. If you know of a neighbor in need, offer to help drive them to a veterinary appointment, foster their pet temporarily or provide a bag of their pet’s favorite food to help close the access to pet care gap. The HSUS is inviting the public to show their support for this campaign by sharing why their animal companion is #MoreThanAPet to them, at humanesociety.org/morethanapet. Campaign partner Smalls is donating a bowl of food for every photo shared, up to $1M, to pets and their families in need. Learn More and Get Involved About Kitty Block Kitty Block is the chief executive officer and president of the Humane Society of the United States and also chief executive officer of Humane Society International. She leads the nation's most effective animal protection organization in the fight for all animals. Block was named president and CEO of the Humane Society of the United States in January 2019, becoming the first woman to hold the position in the organization’s history. Block first joined the HSUS as a legal investigator in 1992 and was instrumental in bringing cruelties such as horse slaughter and the killing of dogs and cats for their fur in China to light. She led the HSUS’s efforts to secure protections for dolphins with successful litigation and landmark dolphin-safe tuna legislation. In addition, she was one of the architects of a successful lawsuit over commercial whaling brought against Japan by Australia in the International Court of Justice. She has served as an adviser to the White House on trade and the environment, and she has served multiple elected terms on the International Dolphin Conservation Agreement International Review Panel, which works with governments on monitoring violations of the agreement. Block received a law degree from The George Washington University in 1990 and a bachelor’s degree in communications and philosophy from the University of New Hampshire in 1986. She is a lifelong animal lover who helped her mother rescue and care for pets and other animals in need as a child. Block lives in Washington, D.C., with her husband and daughter, their street dog rescue, Lilly, and rescue cats, Misti and Storm Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 22, 2023 10:15 AM Eastern Daylight Time

Video

Shareholder to Address Censorship Policies at Alphabet, Amazon, and Meta

National Legal & Policy Center

Following the exposure by the “Twitter Files” reports that revealed the extent to which malicious government agencies colluded with Big Tech to censor content, a shareholder in three Silicon Valley corporations will present proposals in the coming weeks to address their suppression of speech. National Legal and Policy Center – which owns stock in Amazon, Alphabet (parent of Google and YouTube) and Meta (parent of Facebook) – will sponsor proposals at each company that request transparency about requests they have received from U.S. government officials to “take down” content from their platforms. Amazon’s annual meeting is on Wednesday, May 24; Meta’s is on May 31, and Alphabet’s is on June 2. “As we’ve learned since Elon Musk took over Twitter, there is an epidemic of unconstitutional government censorship of speech in our country, and Big Tech has welcomed the opportunities to be their enforcers,” said Paul Chesser, director of NLPC’s Corporate Integrity Project, who will present the proposals at the companies’ respective meetings. “It is vital, as public companies, that Alphabet, Amazon and Meta act in the country’s interest and disclose who in the federal government is making these improper – and most of them probably illegal – requests, and divulge what they have asked to be removed from their platforms.” The Amazon and Meta proposals seek an itemization of the requests the companies have received from federal government. The Alphabet proposal asks for a report about the extent its censorship policies and practices have on the fiduciary health of the company. The text of NLPC’s proposal for a “Risk Audit on Content Censorship” for Alphabet’s 2023 annual meeting follows: RESOLVED: Shareholders request that Alphabet Inc. (“Company”) issue a report at reasonable cost – omitting proprietary or legally privileged information – reviewing the vulnerabilities of its enforcement of Google’s and YouTube’s Terms of Service related to content policies, and assessing the risks posed by content management controversies related to issues such as election interference, freedom of expression, and inequitable application of policies, and how they affect the Company’s finances, operations, and reputation. SUPPORTING STATEMENT: Evidence has accumulated over many years that show Alphabet Inc.’s platforms discriminate against disfavored speech, interfered in elections, and is undeniably prejudiced. Major examples include: In leaked Company emails, employees discussed using “ephemeral experiences” to change users’ views. Back in 2016, the Company’s chief financial officer said, “we will use the great strength and resources and reach we have” to advance Google’s values. Consequentially, senior research psychologist Dr. Robert Epstein found that – based on 1.5 million search experiences his team aggregated in 2020 – that the Company’s manipulations could have shifted up to six million votes to Joe Biden. A study of voter outreach by 2020 political candidates, conducted by North Carolina State University’s Department of Computer Science, found that Google’s Gmail “marked 59.3% more emails from [conservative] candidates as spam compared to the [progressive] candidates.” The Republican National Committee claimed that Gmail sent more than 22 million of its emails to spam during a critical fundraising period in the 2022 election cycle. The Company has incurred a lawsuit and a complaint to the Federal Elections Commission due to the alleged suppression. A Media Research Center analysis of the most tightly contested 2022 U.S. Senate races found that ten of 12 Republican candidates’ campaign websites (83%) appeared far lower (or did not appear at all) on page one of Google’s organic search results, compared to their Senate Democratic Party opponents’ campaign websites. In addition to the above examples, the Company is the target of a credible, major lawsuit by the states of Missouri and Louisiana, based on extensive evidence that the Company violated users’ First Amendment rights. Shareholders need to know whether the Company is engaged in unconstitutional censorship, and whether the Company exercises its content moderation in violation of its Terms of Service, opening the Company to liability claims by victims. Shareholders also need to know whether the Company is failing to disclose these potential liabilities as material risks in its public filings. There is currently no single source providing shareholders the information sought by this resolution. Founded in 1991, NLPC promotes ethics in public life and government accountability through research, investigation, education, and legal action. ### For more information or to schedule an interview with Paul Chesser, contact Dan Rene at 202-329-8357 or drene@nlpc.org. Please visit http://www.nlpc.org. Contact Details National Legal and Policy Center Dan Rene +1 202-329-8357 drene@nlpc.org Company Website http://www.nlpc.org

May 22, 2023 10:00 AM Eastern Daylight Time

From Jam Session to Record Contract: Meet “BANDED”, America’s Newest Music Competition Series

YourUpdateTV

Are you ready to discover the next big music super band? “BANDED” is a first-of-its-kind music competition series that takes you behind the scenes of the music industry and lets you witness the birth of the next big music band. Recently, Brandon Jenner, Host of “BANDED”, and Mark Schulman, “BANDED” Judge conducted a satellite media tour to talk about the show. A video accompanying this announcement is available at: https://youtu.be/JqTjH3jvu10 AXS TV —a subsidiary of Anthem Sports & Entertainment, Inc. —puts the spotlight on rising stars from across the country in the all-new original music competition BANDED, an innovative series that redefines the traditional “build-a-band” concept and showcases exceptional up-and-coming artists who can play, write, and sing. BANDED episodes will premiere every Saturday at 9 p.m. ET. on AXS TV. The series also will roll out weekly across all AXS TV digital channels. BANDED is hosted by musician and television personality Brandon Jenner, with recording artist and American Idol finalist Didi Benami as co-host. In the series premiere, 25 contenders were placed into five brand new multi-genre bands under the tutelage of GRAMMY®-winning and -nominated songwriters, producers, and artists such as Songwriters Hall of Fame honoree Wendy Starland, credited with discovering and developing Lady Gaga; as well as Paul Ebersold, Steve Diamond, Justin Wilson, and Dave Pahanish. Each week will feature a roster of legendary mentors and guest judges from across the music spectrum, such as Metal icons Vince Neil and Kip Winger; chart-topping Country star Steve Azar; Vans Warped Tour mastermind Kevin Lyman; and world-class rock ‘n roll drummer Mark Schulman, among many others. The inaugural season presents eight all-new episodes, with six hour-long episodes bookended by the 90-minute season premiere and season finale. A special video podcast will accompany each episode, as BANDED contestants, and stars breakdown all the latest happenings from the show. “We are extremely pleased to announce our partnership with AXS TV in launching the inaugural season of BANDED,” said Nico Albano, Executive Producer of the series. “AXS TV’s national and digital platforms are incredibly robust, giving viewers multiple ways to conveniently enjoy our content. We hope that this will be the beginning of a long-lasting relationship between AXS TV and BANDED, and we look forward to continuing to work with them as we move forward into the future.” “ BANDED is the perfect complement to our growing lineup of all-new original music-themed programming, putting a fresh spin on the standard music competition format that brings viewers into the fascinating creative process that each band undertakes,” said Katie Daryl, AXS TV’s Vice President of Programming. “We have some truly talented competitors and world-class mentors onboard, and we cannot wait to share all of this and more with our audience when BANDED premieres on AXS TV’s platforms next month.” GameTV will be the exclusive Canadian broadcaster of BANDED. The series will air every Saturday at 7 p.m. ET on GameTV, beginning July 8. “We are excited to be the exclusive home in Canada, and look forward to premiering it this summer,” said Maria Donatelli, Director of Programming for GameTV. Series sponsors include Embassy Suites by Hilton Nashville Downtown, Verijet, Colgate Optic White, Maggiano’s Little Italy, Bulova/Citizen, PRS Guitars, Roland, Gretsch, Zildjian, DW, Fender, and Remo. For more information, please visit www.BANDEDtv.com. Show Teaser About BANDED BANDED, produced by Shadow Entertainment Group, is the first music reality competition show that focuses on the musical talents of the contestants. It aims to give viewers an inside look into the real artistry of creating music. Leveraging highly successful mentors and judges, BANDED will take viewers behind the scenes to witness magic in the making. For more information about the show visit www.BANDEDtv.com About AXS TV AXS TV is a leading multi-platform music and entertainment digital platform and television company owned and operated by Anthem Sports & Entertainment, Inc. AXS TV’s broad library offers content headlined by concerts and music-inspired programming, world-class professional wrestling and MMA. AXS TV’s signature programs include The Top Ten Revealed, The Very VERY Best of the 80s, and Parking Lot Payday. The channel also is the home of IMPACT Wrestling, New Japan Pro-Wrestling and Invicta Fighting Championships. AXS TV is available nationally in the United States, and parts of Canada and the Caribbean. Additionally, AXS TV’s digital programming can be enjoyed on several different platforms including the AXS.TV website and the Network’s app AXS TV NOW, and FAST Channel, as well as on the Network’s official YouTube channel, Facebook and Instagram pages, Twitter and TikTok profiles. For a full list of providers and territories, please visit axs.tv/subscribe. About GameTV GameTV is Canada’s leading destination for game shows and entertainment, powered by a rich programming lineup that boasts both classic and modern game shows as well as a wide selection of reality-based series, back-to-back nightly movies, documentaries and more. Game TV is the home of the most recognizable game shows and is the exclusive broadcaster of the UK produced series The Masked Dancer and The Masked Singer. GameTV is available nationally on Bell, Cogeco, Telus, Rogers, Shaw and Videotron, among others. For more information about the network, visit www.gametvnetwork.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

May 19, 2023 02:10 PM Eastern Daylight Time

Video

UAT Group Reached Agreement with Strategic Capital Partner

Umbra Applied Technologies Group, Inc.

Umbra Applied Technologies Group, Inc. (OTC: UATG) announced today that it has reached an agreement with a strategic capital partner to support the growth of its subsidiary Ossifix Orthopedics. The private equity firm specializes in the medical field. The firm’s focus provides strategic growth capital and works with existing management to increase sales, benefiting both its own investors and value for all Ossifix shareholders. As part of the agreement, the new partner will become a nine percent stakeholder in Ossifix Orthopedics and will provide up to $2 million in funding capital. The firm will also provide additional value such as its investors and relationships to include an extensive portfolio of surgeons, medical facilities and knowledgebase, which will be utilized to further expand marketing and sales for Ossifix. Chief Financial Officer, Thomas Crom stated, “Although this reduces our ownership in Ossifix it dramatically increases Ossifx capability to move forward without any dilution to UATG’s shareholders. This Ossix transaction illustrates the creative ways UATG can fund its subsidiaries without diluting its current UATG shareholders. This type of funding is complex and time-consuming but illustrates Ossifix’s intrinsic value is now being recognized by others.”. This announcement on Friday came amid growing optimism among the Company’s executives that the traction the UAT Group conglomerate has gained in the first half of the year will exceed its expectations for the year; positioning it for a remarkable year. The investment into Ossifix contributes to the Company's consolidated growth initiatives which include augmenting existing product offerings and service capabilities of its subsidiaries as well as positioning infrastructure resources in support of planned expansion. UAT Group Chairman, Alex Umbra commented, “As always, UAT Group stands ready to support each of our subsidiaries, in any way necessary, as we capitalize on the values we create together. This new relationship will not only provide strategic capital but will continue to support growth objectives that will bolster shareholder value, streamline balance sheet debt and enable verticals to be realized sooner”. About Umbra Applied Technologies Group, Inc. The firm is located in Tampa, Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries. For more information, visit: www.uatgroup.com Investor and Media Contact: info@uatgroup.com For more information about Ossifix Technologies, go here: https://ossifixtech.com/ NEITHER THE SECURITIES EXCHANGE COMMISSION NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE. Forward-Looking Information This news release may include "forward-looking statements" including forecasts, estimates, expectations, and objectives for future operations including but not limited to its ability to conclude a business combination with a third party, sale of assets, return of capital or initial public offering and a secondary listing on the OTC as a result of aforementioned and its ability to fund the exploration of its assets through the raising of equity or debt capital or through funding by a joint venture partner that are subject to a number of assumptions, risks, and uncertainties, many of which are beyond the control of Umbra Applied Technologies Group including but not limited to capital markets and securities risks and continued development success on technology. There can be and are no actual or implied guarantees that any of the above activities will be completed or completed on terms acceptable to the Company and its shareholders or approved by any regulatory authority having jurisdiction. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Umbra Applied Technologies Group does not assume the obligation to update any forward-looking statement, except as required by applicable law. Contact Details Umbra Applied Technologies Group, Inc. info@uatgroup.com

May 19, 2023 08:00 AM Eastern Daylight Time

AmeriLife’s ORCA Life Welcomes Advance Planning Partners

AmeriLife

ORCA Life, a leader in the final expense insurance market and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has formally partnered with Advance Planning Partners. Per the agreement, terms of the deal were not disclosed. Advance Planning Partners is a Louisville-based final expense shop with offices in Denver, Houston, Charlotte and Morgantown, W.Va. The firm’s co-owners, Richard Shawn and Michael Huffman, were founding members of ORCA Life in 2016. Now, together with ORCA and alongside its founder and president, Glenn Crabtree, Advance Planning Partners will have expanded access to the best-in-class leadership and resources of ORCA and AmeriLife, including new products and solutions in the Medicare and retirement income space. “Richard and Michael have been a part of the fabric of ORCA Life since the beginning, and today’s announcement is the culmination of our longstanding partnership and belief in what we’ve build together,” said Crabtree. “I couldn’t be more excited to welcome Advance Planning Partners into the fold, and we look forward to helping them continue to grow their company.” Advance Planning Partners will continue to operate under the ORCA banner, while both Shawn and Huffman will remain in their roles as members of ORCA’s executive leadership team. “I’m incredibly proud of what we’ve built at Advance Planning Partners, and am thrilled to make our longstanding connection with ORCA Life official,” said Shawn. “We’ve only scratched the surface of our potential. The sky’s truly the limit as we venture into new territory with more diverse product offerings and the backing of ORCA and AmeriLife.” “This is, indeed, an exciting day, not only for me and Richard, but for our affiliated agents as well,” added Huffman. “This new yet familiar partnership will not only serve to accelerate our company’s growth, but also ensure that our agents are armed with the very best tools, technology and contracts to take their books of business to the next level.” “I’m thrilled to welcome Richard and Michael to the AmeriLife family of companies under Glenn’s and ORCA Life’s continued guidance,” said Scotty Elliott, AmeriLife’s Chief Distribution Officer for Health. “Since partnering with ORCA in 2021, AmeriLife has witnessed firsthand their team’s uncompromising drive to deliver for their clients. The addition of Advance Planning Partners will undoubtedly strengthen both organizations, and we’re excited to further fuel their collective success.” ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and 120 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

May 18, 2023 01:00 PM Eastern Daylight Time

Emergent Health Executes Term Sheet and Engagement Letter with Boustead Securities to roll up its Subsidiary, Evolutionary Biologics and other regenerative medicine and products companies

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced that it has executed a Term Sheet and Engagement Letter with Boustead Securities to roll up its subsidiary Evolutionary Biologics and other regenerative medicine and regenerative biologic products companies with NO DILUTION to the Emergent Shareholders with a planned $10 million initial capital raise and public offering and application for listing on NASDAQ or NYSE/AMEX. Emergent’s subsidiary, Evolutionary Biologics, and the new brand called Maximus Men’s Health, along with Juventix Regenerative Medical and Interactive Practice Solutions and Nanosthetic. Subsequent to the IPO, Emergent plans to distribute the shares received by Emergent from the sale of Evolutionary Biologics as a dividend to its shareholders, pro rata at NO COST to the Emergent Shareholders. Such a dividend would only occur after Emergent files a Registration Statement with the SEC and it is declared effective. Any potential taxable event resulting from such a dividend would be the responsibility of each individual shareholder, and Emergent advises each shareholder to consult with their professional advisors, and makes no representation as to the taxable or nontaxable event. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. Jim Morrison, former L'Oréal President and Emergent’s full time CEO stated, “Boustead Securities is a world class financial organization. They approached us to participate in rolling up a series of regenerative biologics into a brand-new IPO. When you look at the effect that this transaction, and the previously announced PharmaZu transaction, will have on EMGE, it's amazing. We see this as a great way to maximize valuation for our Company and take EMGE to the next level.” ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website info@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 18, 2023 09:00 AM Eastern Daylight Time

Image

Lifestyle

BioNTech's mRNA Vaccine Shows Early Potential Against Pancreatic Cancer

OYO Launches Discounted Stays as Memorial Day Weekend Bookings Soar

Emergent Health and Apollo Biowellness Announce Strategic Collaboration

The Humane Society of the United States Addresses the Pet Poverty Crisis

Shareholder to Address Censorship Policies at Alphabet, Amazon, and Meta

From Jam Session to Record Contract: Meet “BANDED”, America’s Newest Music Competition Series

UAT Group Reached Agreement with Strategic Capital Partner

AmeriLife’s ORCA Life Welcomes Advance Planning Partners

Emergent Health Executes Term Sheet and Engagement Letter with Boustead Securities to roll up its Subsidiary, Evolutionary Biologics and other regenerative medicine and products companies